First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
Orion to receive an upfront payment of USD 290 million
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Bringing next-gen cannabinoid therapeutics to cancer patients
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Subscribe To Our Newsletter & Stay Updated
